Earnings Releases·Nov 12, 2026, 4:16 PM ET

AnaptysBio — Fiscal First Quarter 2027 Earnings Summary

Collaboration revenue declined to $30.3 million from $76.3 million year-over-year due to the absence of $50 million in milestone revenue recognized in Q3 2025, partially offset by an 11% quarter-over-quarter increase in Jemperli royalties.
Net income from continuing operations fell to $3.9 million ($0.13 per share) from $56.3 million ($2.02 per share) in the prior year period, driven by a $10.5 million increase in general and administrative expenses, including $4.8 million in legal costs for GSK and Tesaro litigation.
Jemperli global net sales grew 20% year-over-year to $365 million for the quarter and 29% to $1.0 billion for the nine-month period, with the company projecting over $390 million in annualized royalties by 2029.
Strategic outlook includes a PDUFA decision for Quimilza on December 12, 2026, expected regulatory submissions for Jemperli in Japan (H1 2027) and Europe/China (H2 2027), and anticipated paydown of approximately $270 million in non-recourse debt to Sagard in H2 2027.
The company holds $153.0 million in cash and investments as of September 30, 2026, while a judgment in the GSK/Tesaro litigation is expected in Q4 2026 or Q1 2027.